Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a gateway to the proteome. The Company’s initial product, the Proteograph Product Suite (Proteograph), is an integrated solution that includes engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. Proteograph leverages its engineered nanoparticle (NP) technology to provide large-scale access to the proteome. Its engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide level, including protein variants. It is focused on adoption of the Proteograph with customers in the proteomics and genomics markets. The Company is initially focused on research applications for the Proteograph product suite and is selling and marketing the Proteograph for research use only (RUO).
|Latest Earnings Beat Consensus (Q4 ending 12/2022)||Next Earnings Announcement|
GAAP vs. Non-GAAP Earnings
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
Announced March 2, 2023
of 4 analysts
|(Unconfirmed) May 2, 2023|
Draw up to 3 lines inside the chart.
SEER's fiscal year ends in December
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.